Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT07232212

Survival Outcomes of Gynecologic Oncology Patients at Assiut University

This retrospective cohort study investigates survival outcomes of gynecological oncology patients treated at Assiut University Hospital between 2022 and 2025, comparing them to international benchmarks and assessing factors affecting survival.

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Conditions

Gynaecological Oncology

Sex eligibility

Female

Study type

Observational

About this study

The study aims to evaluate overall survival (OS) and progression-free survival (PFS) of patients diagnosed with gynecological cancers (including ovarian, cervical, endometrial, vulvar, and vaginal cancers) and treated at Assiut University Hospital from January 1, 2022, to December 31, 2025. Using retrospective medical records and pathology reports, the study will analyze demographic, clinical, and treatment-related variables to identify factors influencing survival outcomes. Assiut University is a tertiary care center in a low-resource setting; thus, the study will also assess adherence to international oncology guidelines (e.g., ESMO, ASCO) and compare local survival rates with international standards. Statistical methods include Kaplan-Meier survival analysis and Cox proportional hazards modeling.

Who can participate

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patients diagnosed with gynecological cancers (ovarian, cervical, endometrial, vulvar, vaginal)

Patients treated at Assiut University Gynecological Oncology Department between January 1, 2022, and December 31, 2025

All age groups included

Exclusion criteria

  • Patients with non-gynecological malignancies or metastatic cancers originating outside the gynecological tract

Patients with incomplete medical records (e.g., missing pathology reports or treatment details)

Patients with significant comorbidities independently affecting survival (e.g., advanced heart failure, severe liver or renal disease, terminal illnesses unrelated to cancer)

Treatment and study plan

Primary outcomes

  1. Overall Survival

    Time frame: 4 years

    Overall survival (OS) is defined as the duration of time from the date of cancer diagnosis or initiation of treatment until death from any cause. Patients will be censored at the date of last follow-up if alive at study end. This outcome will provide a direct estimate of survival rates among gynecological oncology patients treated at Assiut University Hospital.

Sponsors and collaborators

Lead sponsor

Assiut University

Other

Registry information

Official study title

Survival Outcomes of Gynecological Oncology Patients at Assiut University: A Retrospective Study (2022-2025)

Important dates

Study start
2026
Primary completion
2027
Study completion
2027
First posted
Nov 18, 2025
Registry last updated
Nov 18, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.